285 related articles for article (PubMed ID: 27376373)
1. Efficacy and Treatment Costs of Monotherapy with bDMARDs in the Treatment of Rheumatoid Arthritis in Patients Intolerant to or Inappropriate to Continue Treatment with Methotrexate.
Batticciotto A; Ravasio R; Riva M; Sarzi-Puttini P
Adv Ther; 2016 Aug; 33(8):1360-73. PubMed ID: 27376373
[TBL] [Abstract][Full Text] [Related]
2. Adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, tocilizumab and abatacept for the treatment of rheumatoid arthritis not previously treated with disease-modifying antirheumatic drugs and after the failure of conventional disease-modifying antirheumatic drugs only: systematic review and economic evaluation.
Stevenson M; Archer R; Tosh J; Simpson E; Everson-Hock E; Stevens J; Hernandez-Alava M; Paisley S; Dickinson K; Scott D; Young A; Wailoo A
Health Technol Assess; 2016 Apr; 20(35):1-610. PubMed ID: 27140438
[TBL] [Abstract][Full Text] [Related]
3. Economic evaluation of tocilizumab monotherapy compared to adalimumab monotherapy in the treatment of severe active rheumatoid arthritis.
Carlson JJ; Ogale S; Dejonckheere F; Sullivan SD
Value Health; 2015 Mar; 18(2):173-9. PubMed ID: 25773552
[TBL] [Abstract][Full Text] [Related]
4. Cost-utility analysis of certolizumab pegol in combination with methotrexate in patients with moderate-to-severe active rheumatoid arthritis in Greece.
Tzanetakos C; Tzioufas A; Goules A; Kourlaba G; Theodoratou T; Christou P; Maniadakis N
Rheumatol Int; 2017 Sep; 37(9):1441-1452. PubMed ID: 28523420
[TBL] [Abstract][Full Text] [Related]
5. Mean cost per number needed to treat with tocilizumab plus methotrexate versus abatacept plus methotrexate in the treatment of rheumatoid arthritis in patients previously treated with methotrexate.
Benucci M; Ravasio R; Damiani A
Clinicoecon Outcomes Res; 2017; 9():403-410. PubMed ID: 28765712
[TBL] [Abstract][Full Text] [Related]
6. Economic Evaluation of Sarilumab in the Treatment of Adult Patients with Moderately-to-Severely Active Rheumatoid Arthritis Who Have an Inadequate Response to Conventional Synthetic Disease-Modifying Antirheumatic Drugs.
Muszbek N; Proudfoot C; Fournier M; Chen CI; Kuznik A; Kiss Z; Gal P; Michaud K
Adv Ther; 2019 Jun; 36(6):1337-1357. PubMed ID: 31004324
[TBL] [Abstract][Full Text] [Related]
7. [Economic evaluation of rheumathoid arthritis monotherapy with tocilizumab and adalimumab].
Navarro Sarabia F; Blanco FJ; Álvaro Gracia JM; García Meijide JA; Poveda JL; Rubio-Rodríguez D; Rubio-Terrés C
Rev Esp Salud Publica; 2013; 87(4):343-50. PubMed ID: 24100773
[TBL] [Abstract][Full Text] [Related]
8. Treatment Patterns and Costs in Biologic DMARD-Naive Patients with Rheumatoid Arthritis Initiating Etanercept or Adalimumab with or Without Methotrexate.
Tkacz J; Gharaibeh M; DeYoung KH; Wilson K; Collier D; Oko-Osi H
J Manag Care Spec Pharm; 2020 Mar; 26(3):285-294. PubMed ID: 32105179
[TBL] [Abstract][Full Text] [Related]
9. Treatment Patterns, Direct Cost of Biologics, and Direct Medical Costs for Rheumatoid Arthritis Patients: A Real-world Analysis of Nationwide Japanese Claims Data.
Sugiyama N; Kawahito Y; Fujii T; Atsumi T; Murata T; Morishima Y; Fukuma Y
Clin Ther; 2016 Jun; 38(6):1359-1375.e1. PubMed ID: 27101816
[TBL] [Abstract][Full Text] [Related]
10. Cost-effectiveness of adalimumab, etanercept, and tocilizumab as first-line treatments for moderate-to-severe rheumatoid arthritis.
Soini EJ; Hallinen TA; Puolakka K; Vihervaara V; Kauppi MJ
J Med Econ; 2012; 15(2):340-51. PubMed ID: 22168785
[TBL] [Abstract][Full Text] [Related]
11. Head-to-head comparison of certolizumab pegol versus adalimumab in rheumatoid arthritis: 2-year efficacy and safety results from the randomised EXXELERATE study.
Smolen JS; Burmester GR; Combe B; Curtis JR; Hall S; Haraoui B; van Vollenhoven R; Cioffi C; Ecoffet C; Gervitz L; Ionescu L; Peterson L; Fleischmann R
Lancet; 2016 Dec; 388(10061):2763-2774. PubMed ID: 27863807
[TBL] [Abstract][Full Text] [Related]
12. Treatment Persistence and Healthcare Costs Among Patients with Rheumatoid Arthritis Changing Biologics in the USA.
Chastek B; Chen CI; Proudfoot C; Shinde S; Kuznik A; Wei W
Adv Ther; 2017 Nov; 34(11):2422-2435. PubMed ID: 29039054
[TBL] [Abstract][Full Text] [Related]
13. Comparative effectiveness of first-line biological monotherapy use in rheumatoid arthritis: a retrospective analysis of the RECord-linkage On Rheumatic Diseases study on health care administrative databases.
Silvagni E; Bortoluzzi A; Carrara G; Zanetti A; Govoni M; Scirè CA
BMJ Open; 2018 Sep; 8(9):e021447. PubMed ID: 30206082
[TBL] [Abstract][Full Text] [Related]
14. Current evidence for the management of rheumatoid arthritis with biological disease-modifying antirheumatic drugs: a systematic literature review informing the EULAR recommendations for the management of RA.
Nam JL; Winthrop KL; van Vollenhoven RF; Pavelka K; Valesini G; Hensor EM; Worthy G; Landewé R; Smolen JS; Emery P; Buch MH
Ann Rheum Dis; 2010 Jun; 69(6):976-86. PubMed ID: 20447957
[TBL] [Abstract][Full Text] [Related]
15. An Economic Evaluation of Tofacitinib Treatment in Rheumatoid Arthritis: Modeling the Cost of Treatment Strategies in the United States.
Claxton L; Jenks M; Taylor M; Wallenstein G; Mendelsohn AM; Bourret JA; Singh A; Moynagh D; Gerber RA
J Manag Care Spec Pharm; 2016 Sep; 22(9):1088-102. PubMed ID: 27579831
[TBL] [Abstract][Full Text] [Related]
16. Tocilizumab after a first-line with anti-TNF in rheumatoid arthritis: a cost-consequence analysis in the Italian setting.
Iannazzo S; Benucci M; Favalli EG
Clin Exp Rheumatol; 2018; 36(3):479-485. PubMed ID: 29352843
[TBL] [Abstract][Full Text] [Related]
17. Certolizumab Pegol for Treating Rheumatoid Arthritis Following Inadequate Response to a TNF-α Inhibitor: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.
Bermejo I; Stevenson M; Archer R; Stevens JW; Goka E; Clowes M; Scott DL; Young A
Pharmacoeconomics; 2017 Nov; 35(11):1141-1151. PubMed ID: 28550592
[TBL] [Abstract][Full Text] [Related]
18. Cost-effectiveness of sequenced treatment of rheumatoid arthritis with targeted immune modulators.
Jansen JP; Incerti D; Mutebi A; Peneva D; MacEwan JP; Stolshek B; Kaur P; Gharaibeh M; Strand V
J Med Econ; 2017 Jul; 20(7):703-714. PubMed ID: 28294642
[TBL] [Abstract][Full Text] [Related]
19. Rheumatoid arthritis treated with 6-months of first-line biologic or biosimilar therapy: an updated systematic review and network meta-analysis.
Simpson EL; Ren S; Hock ES; Stevens JW; Binard A; Pers YM; Archer R; Paisley S; Stevenson MD; Herpin C; Ghabri S
Int J Technol Assess Health Care; 2019 Jan; 35(1):36-44. PubMed ID: 30722803
[TBL] [Abstract][Full Text] [Related]
20. Pharmacoeconomic analysis of biological disease modifying antirheumatic drugs in patients with rheumatoid arthritis based on real-world data from the IORRA observational cohort study in Japan.
Tanaka E; Inoue E; Yamaguchi R; Shimizu Y; Kobayashi A; Sugimoto N; Hoshi D; Shidara K; Sato E; Seto Y; Nakajima A; Momohara S; Taniguchi A; Yamanaka H
Mod Rheumatol; 2017 Mar; 27(2):227-236. PubMed ID: 27472516
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
